Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.600
+0.050 (3.23%)
At close: Feb 11, 2026, 4:00 PM EST
1.618
+0.018 (1.13%)
After-hours: Feb 11, 2026, 7:51 PM EST
Cardiff Oncology Stock Forecast
CRDF's stock price has decreased by -65.07% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Cardiff Oncology stock have a consensus rating of "Strong Buy" and an average price target of $10.83, which forecasts a 576.88% increase in the stock price over the next year. The lowest target is $3.50 and the highest is $19.
Price Target: $10.83 (+576.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cardiff Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +525.00% | Jan 28, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $10 | Strong Buy | Maintains | $18 → $10 | +525.00% | Aug 6, 2025 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +1,087.50% | Jul 8, 2025 |
| Jefferies | Jefferies | Hold Initiates $3.5 | Hold | Initiates | $3.5 | +118.75% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $17 → $18 | Strong Buy | Maintains | $17 → $18 | +1,025.00% | May 9, 2025 |
Financial Forecast
Revenue This Year
470.33K
from 683.00K
Decreased by -31.14%
Revenue Next Year
339.15K
from 470.33K
Decreased by -27.89%
EPS This Year
-0.78
from -0.95
EPS Next Year
-0.78
from -0.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 525,000 | 729,750 | ||||
| Avg | 470,332 | 339,150 | ||||
| Low | 343,000 | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -23.1% | 55.2% | ||||
| Avg | -31.1% | -27.9% | ||||
| Low | -49.8% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.78 | -0.58 | ||||
| Avg | -0.78 | -0.78 | ||||
| Low | -0.82 | -0.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.